About the Osteosarcoma Session
Osteosarcoma is a malignant bone tumor predominantly affecting adolescents and young adults. Recent cancer research focuses on understanding its genetic and molecular underpinnings to develop targeted therapies. Advances in genomics have identified key mutations and pathways, such as the RB1 and TP53 genes, involved in tumor development. Immunotherapy, particularly the use of immune checkpoint inhibitors, is being explored to enhance the body's immune response against osteosarcoma cells. Additionally, researchers are investigating the tumor microenvironment to identify new therapeutic targets. Despite challenges, these efforts aim to improve prognosis and survival rates for osteosarcoma patients through precision medicine and novel treatment strategies.
Topics Covered in Osteosarcoma
Genomic Instability
Germline Predisposition
Neoadjuvant Chemotherapy
Histologic Response
Limb-Sparing Surgery
Pulmonary Metastases
Related Scientific Sessions at CIOC 2027
Why Attend the Osteosarcoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Osteosarcoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Osteosarcoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Osteosarcoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Osteosarcoma Conference 2027 — FAQs
What is the Osteosarcoma track at CIOC 2027?
The Osteosarcoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Osteosarcoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Osteosarcoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Osteosarcoma are all welcome — whether presenting or attending.
Can I present my research in the Osteosarcoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Osteosarcoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Osteosarcoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.